Research Highlights: An analysis of a clinical trial of more than 2,500 people with Type 2 diabetes and kidney disease found that high levels of four biomarkers are strongly predictive for the development of heart and kidney issues. People who took canagliflozin, a sodium glucose co-transporter 2 inhibitor (SGLT2 inhibitor), had lower levels of the four biomarkers compared to those who took a placebo over the three-year study period. Treatment with canagliflozin helped to substantially reduce the risk of hospitalization for heart failure and other heart complications among patients considered to have the highest risk.

https://www.miragenews.com/blood-test-may-foretell-heart-kidney-risk-in-1069144/

#miragenews